Cabazitaxel Plus Lapatinib as Therapy for HER2+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study.

MLA

Yardley, Denise A., et al. “Cabazitaxel Plus Lapatinib as Therapy for HER2+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-Finding Study.” Clinical Breast Cancer, vol. 18, no. 5, Oct. 2018, pp. e781–87. EBSCOhost, https://doi.org/10.1016/j.clbc.2018.03.004.

APA

Yardley, D. A., Hart, L. L., Ward, P. J., Wright, G. L., Shastry, M., Finney, L., DeBusk, L. M., & Hainsworth, J. D. (2018). Cabazitaxel Plus Lapatinib as Therapy for HER2+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study. Clinical Breast Cancer, 18(5), e781–e787. https://doi.org/10.1016/j.clbc.2018.03.004

Chicago

Yardley, Denise A., Lowell L. Hart, Patrick J. Ward, Gail L. Wright, Mythili Shastry, Lindsey Finney, Laura M. DeBusk, and John D. Hainsworth. 2018. “Cabazitaxel Plus Lapatinib as Therapy for HER2+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-Finding Study.” Clinical Breast Cancer 18 (5): e781–87. doi:10.1016/j.clbc.2018.03.004.